OncoMatch/Clinical Trials/NCT02391051
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
Is NCT02391051 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT2A, CN0, CM0 (clinical TNM)
Grade: Gleason Score ≤ 6 (3+3) (Gleason)
Tumor stage: cT1-2a cN0 cM0; Tumor stage ≥ T2b [excluded]; Known metastasis: N+ and/or M1 [excluded]; Gleason Score of index lesion ≤ 6 (3+3)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02391051 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage CT2A or CN0 or CM0 is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages